Clinical significance of DNMT3A R882 mutation in acute myeloid leukemia

ObjectiveTo investigate the mutation of DNA methyltransferase 3A(DNMT3A) R882 in patients with acute myeloid leukemia(AML), and analyze the characteristics of related clinical data.

MethodsThe mutations of DNMT3A R882 in 116 patients with AML and 30 patients with iron deficiency anemia were detected using DNA gene sequencing.

ResultsAmong 116 patients with AML, 16 cases with DNMT3A R882 mutation were identified, which included 9 cases with R882H mutation and 7 cases with R882C mutation, all mutations were heterozygous mutations, while there was not mutation in benign control group.The number of patients with normal karyotype AML(NK-AML), and M4 and M5 in DNMT3A R882 mutation AML(Mut-DNMT3A) group were significantly higher than that in DNMT3A wild type AML(Wild-DNMT3A) group(P < 0.05).The patient age, and white blood cell amount and platelet amount in peripheral blood in Mut-DNMT3A group were significantly higher than those in Wild-DNMT3A group(P < 0.05).The overall survival rate and disease-free survival rate in Mut-DNMT3A group were significantly lower than those in Wild-DNMT3A group(P < 0.05).

ConclusionsDNMT3A R882 mutation is easy to occur in AML patients, especially NK-AML, M4 and M5 patients, and complicated with risk factors of old age and high white blood cell amonut.DNMT3A R882 mutation is a biological marker of poor prognosis in AML patients.